Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
Li V, McKay FC, Tscharke DC, Smith C, Khanna R, Lechner-Scott J, Rawlinson WD, Lloyd AR, Taylor BV, Morahan JM, Steinman L, Giovannoni G, Bar-Or A, Levy M, Drosu N, Potter A, Caswell N, Smith L, Brady EC, Frost B, Hodgkinson S, Hardy TA, Broadley SA; Australian Anti-EBV Drugs for MS Working Group. Li V, et al. Among authors: broadley sa. CNS Drugs. 2025 Jan 10. doi: 10.1007/s40263-024-01153-5. Online ahead of print. CNS Drugs. 2025. PMID: 39792343
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.
Butzkueven H, Ponsonby AL, Stein MS, Lucas RM, Mason D, Broadley S, Kilpatrick T, Lechner-Scott J, Barnett M, Carroll W, Mitchell P, Hardy TA, Macdonell R, McCombe P, Lee A, Kalincik T, van der Walt A, Lynch C, Abernethy D, Willoughby E, Barkhof F, MacManus D, Clarke M, Andrew J, Morahan J, Zhu C, Dear K, Taylor BV; PREVANZ Investigators. Butzkueven H, et al. Brain. 2024 Apr 4;147(4):1206-1215. doi: 10.1093/brain/awad409. Brain. 2024. PMID: 38085047 Free PMC article. Clinical Trial.
The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review.
Marx W, Hockey M, McGuinness AJ, Lane M, Christodoulou J, van der Mei I, Berk M, Dean OM, Taylor B, Broadley S, Lechner-Scott J, Jacka FN, Lucas RM, Ponsonby AL; RELIEF Trial team. Marx W, et al. Mult Scler Relat Disord. 2020 Jan;37:101486. doi: 10.1016/j.msard.2019.101486. Epub 2019 Nov 2. Mult Scler Relat Disord. 2020. PMID: 31707234
Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.
Hardy TA, Aouad P, Barnett MH, Blum S, Broadley S, Carroll WM, Crimmins D, Griffiths D, Hodgkinson S, Lechner-Scott J, Lee A, Malhotra R, McCombe P, Parratt J, Plummer C, Van der Walt A, Martel K, Walker RA. Hardy TA, et al. Mult Scler J Exp Transl Clin. 2024 Jan 12;10(1):20552173231226106. doi: 10.1177/20552173231226106. eCollection 2024 Jan-Mar. Mult Scler J Exp Transl Clin. 2024. PMID: 38222025 Free PMC article.
Long-term disability trajectories in multiple sclerosis: a group-based trajectory analysis of the AusLong cohort.
Zarghami A, Hussain MA, van der Mei I, Simpson-Yap S, Ponsonby AL, Lechner-Scott J, Broadley SA, Lucas RM, Zhou Y, Lin X, Investigator Group A, Taylor BV. Zarghami A, et al. Among authors: broadley sa. J Neurol Neurosurg Psychiatry. 2024 Sep 4:jnnp-2024-333632. doi: 10.1136/jnnp-2024-333632. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39231584
130 results